Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ADMS
Delisted

Adamas Pharmaceuticals Stock Price (Quote)

$8.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $8.22 $8.22 Friday, 27th May 2022 ADMS stock ended at $8.22. During the day the stock fluctuated 0% from a day low at $8.22 to a day high of $8.22.
90 days $8.22 $8.22
52 weeks $4.02 $8.25

Historical Adamas Pharmaceuticals prices

Date Open High Low Close Volume
Jul 21, 2016 $16.24 $16.24 $16.24 $16.24 531 200
Jul 20, 2016 $14.81 $14.81 $14.81 $14.81 316 700
Jul 19, 2016 $14.82 $14.82 $14.82 $14.82 270 500
Jul 18, 2016 $15.18 $15.18 $15.18 $15.18 143 400
Jul 15, 2016 $15.50 $15.50 $15.50 $15.50 197 400
Jul 14, 2016 $15.47 $15.47 $15.47 $15.47 259 900
Jul 13, 2016 $16.14 $16.14 $16.14 $16.14 319 200
Jul 12, 2016 $16.62 $16.62 $16.62 $16.62 324 500
Jul 11, 2016 $15.65 $15.65 $15.65 $15.65 155 100
Jul 08, 2016 $15.69 $15.69 $15.69 $15.69 237 800
Jul 07, 2016 $15.49 $15.49 $15.49 $15.49 188 600
Jul 06, 2016 $15.84 $15.84 $15.84 $15.84 233 900
Jul 05, 2016 $15.38 $15.38 $15.38 $15.38 141 400
Jul 01, 2016 $15.55 $15.55 $15.55 $15.55 258 200
Jun 30, 2016 $15.14 $15.14 $15.14 $15.14 209 300
Jun 29, 2016 $15.48 $15.48 $15.48 $15.48 275 700
Jun 28, 2016 $15.52 $15.52 $15.52 $15.52 432 500
Jun 27, 2016 $14.72 $14.72 $14.72 $14.72 407 800
Jun 24, 2016 $15.52 $15.52 $15.52 $15.52 919 300
Jun 23, 2016 $16.24 $16.24 $16.24 $16.24 247 700
Jun 22, 2016 $16.39 $16.39 $16.39 $16.39 300 100
Jun 21, 2016 $16.62 $16.62 $16.62 $16.62 333 100
Jun 20, 2016 $18.06 $18.06 $18.06 $18.06 320 100
Jun 17, 2016 $17.50 $17.50 $17.50 $17.50 320 400
Jun 16, 2016 $16.87 $16.87 $16.87 $16.87 179 450
Click to get the best stock tips daily for free!

About Adamas Pharmaceuticals

Adamas Pharmaceuticals Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms assoc... ADMS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT